Status:
COMPLETED
Registry of Unexplained Cardiac Arrest
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Kingston Health Sciences Centre
Quebec Heart Institute
Conditions:
Cardiac Arrest
Long QT Syndrome
Eligibility:
All Genders
2+ years
Brief Summary
The CASPER will collect systematic clinical assessments of patients and families within the multicenter Canadian Inherited Heart Rhythm Research Network. Unexplained Cardiac Arrest patients and family...
Detailed Description
Arrhythmias caused by congenital or acquired abnormalities of cardiac K+ or Na+ channels are increasingly recognized as a cause of syncope and sudden death. Cardiac arrest in the absence of overt stru...
Eligibility Criteria
Inclusion
- Cardiac arrest requiring cardioversion or defibrillation.
- Syncope with documented polymorphic ventricular tachycardia felt to be responsible for the index event.
- First degree relative of an index case of UCA undergoing clinical testing.
- First degree relative of a family member with UCA or sudden death before age 35 with a negative autopsy for cause of death, presumed arrhythmic.
- First degree relative of a family member with UCA or sudden death with objective evidence of primary electrical disease, such as a diagnostic electrocardiogram (ECG), exercise test, drug infusion, or genetic testing.
Exclusion
- Coronary artery disease (stenosis \> 50%)
- Reduced left ventricular function (left ventricular ejection fraction \[LVEF\] \< 50%)
- Event managed without an implantable cardioverter defibrillator \[ICD\] (for follow-up portion)
- Unwilling or unable to provide clinical follow-up (for follow-up portion)
- Comorbidity making survival of \> 1 year unlikely
- Persistent resting QTc \> 460 msec for males and 480 msec for females
- Reversible cause of cardiac arrest such as marked hypokalemia (\< 2.8 mmol/l) or drug overdose sufficient in gravity without other cause to explain the cardiac arrest
- Hemodynamically stable sustained monomorphic ventricular tachycardia with a QRS morphology consistent with recognized forms of idiopathic ventricular tachycardia (outflow tract or apical septal)
- Brugada's sign with e2 mm ST elevation in V1 and/or V2
- Unwilling or unable to provide consent
Key Trial Info
Start Date :
May 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
1529 Patients enrolled
Trial Details
Trial ID
NCT00292032
Start Date
May 1 2004
End Date
August 30 2020
Last Update
November 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Vancouver, British Columbia, Canada, V6E 1M7